Abstracts Archive - Page 85 of 2425 - ACR Meeting Abstracts

Abstract Number: 0032 • ACR Convergence 2024
Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis
Wenxian Zhou¹, Michael Duryee², Nozima Aripova², Jill Poole², Carlos Hunter², Amy Nelson², Tate Johnson², Daniel Anderson³, Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: The risk of heart failure (HF) is increased in patients with rheumatoid arthritis (RA), although mechanisms of myocardial dysfunction underlying HF development in RA…
Abstract Number: 0026 • ACR Convergence 2024
Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin
Michael Newton¹, Aanya Mohan², Tareq Hanna³, Dana Orange⁴, John Varga² and Tristan Maerz², ¹University of Michigan, South Lyon, MI, ²University of Michigan, Ann Arbor, MI, ³Wayne State University, Detroit, MI, ⁴The Rockefeller University, New York, NY
Background/Purpose: Synovial fibrosis is a hallmark of osteoarthritis (OA) and a clinical correlate to joint pain. Fibrosis of skin, lungs and other organs is the…
Abstract Number: 0500 • ACR Convergence 2024
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Kevin Winthrop¹, Daniel Aletaha², Roberto Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Vikas Modgill⁶, Edmund V. Ekoka Omoruyi⁷, Dick de Vries⁸, Katrien Van Beneden⁹, Jacques-Eric Gottenberg¹⁰ and Gerd Burmester¹¹, ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁵Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Development, Galapagos BV, Leiden, Netherlands, ⁹Medical Affairs, Galapagos NV, Mechelen, Belgium, ¹⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The oral Janus kinase 1-preferential inhibitor filgotinib (FIL) is approved at doses of 100 mg (FIL100) and 200 mg (FIL200) for the treatment of…
Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef Smolen¹, Ted Mikuls², James Galloway³, Ulf Müller-Ladner⁴, Jeffrey Curtis⁵, Motomu Hashimoto⁶, Tsutomu Takeuchi⁷, Ernest Choy⁸, Yoshiya Tanaka⁹, Carlos Cara¹⁰, Bernard Lauwerys¹¹, Nicola Tilt¹², Baran Ufuktepe¹³ and Peter C. Taylor¹⁴, ¹Medical University of Vienna, Vienna, Austria, ²University of Nebraska Medical Center, Omaha, NE, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴Justus-Liebig University Giessen, Bad Nauheim, Germany, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶Osaka Metropolitan University, Osaka, Japan, ⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁸Cardiff University School of Medicine, Cardiff, United Kingdom, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰UCB Pharma, Madrid, Spain, ¹¹UCB Pharma, Brussels, Belgium, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Istanbul, Turkey, ¹⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
Abstract Number: 0414 • ACR Convergence 2024
Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis
Andrew Grim¹, Yongdong (Dan) Zhao², Christine Wang¹, Erin Janssen³, Jessica Turnier⁴, Anastasia Hyrhorczuk¹ and Nadine Saad¹, ¹University of Michigan, Ann Arbor, MI, ²University of Washington, Redmond, WA, ³CS Mott Children's Hospital, Ann Arbor, MI, ⁴University of Michigan, Saline, MI
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder. Some patients with CNO may present acutely and be misdiagnosed as infectious osteomyelitis (IO).…
Abstract Number: 0448 • ACR Convergence 2024
A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities
Divya Singh¹, Maya Faison², Molly Leavitt³, Megan Clowse⁴ and Cuoghi Edens⁵, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chapel Hill, NC, ³MacNeal Hospital/Loyola Medicine, Chicago, IL, ⁴Duke University, Chapel Hill, NC, ⁵Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: Nearly half of systemic lupus erythematosus (SLE) patients will experience pregnancy complications. These complications include increased rates of prematurity, miscarriage, pre-eclampsia, and mortality. Maternal…
Abstract Number: 0045 • ACR Convergence 2024
Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins
Khushali Trivedi¹, Clarissa Klenke², Jun Kim¹, Jeba Atkia Maisha², Alina Sememenko¹, XIAOBO MENG², Mario Navarrete¹, Hani El-Gabalawy² and Liam O'Neil², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
Abstract Number: 0284 • ACR Convergence 2024
Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
Joanna Potera¹, Angelo Gaffo², Alvin Day³, Mariana Urquiaga² and Amanda Alexander⁴, ¹University of Alabama at Birmingham, Irondale, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Dept. of Veterans Affairs, Lexington, SC, ⁴University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Calcium pyrophosphate deposition disease is a common condition that can cause chronic polyarticular inflammatory joint disease, which sometimes resembles rheumatoid arthritis. Misdiagnosis is especially…
Abstract Number: 0520 • ACR Convergence 2024
Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Yoichi Nakayama¹, Daijiro Kabata², Wataru Yamamoto³, Hidehiko Makino⁴, Koji Nagai⁴, Naofumi Yoshida⁵, Yonsu Son⁵, Masaki Katayama⁶, Hirotaka Yamada⁷, Keisuke Nishimura⁷, Ryota Hara⁸, Ryu Watanabe⁹, Yuki Etani¹⁰, Kosuke Ebina¹¹, Hideo Onizawa¹², Takayuki Fujii¹³, Akira Onishi¹⁴, Kosaku Murakami¹⁵, Koichi Murata¹², Masao Tanaka¹⁴, Shuichi Matsuda¹², Akio Morinobu¹⁶, Ayumi Shintani² and Motomu Hashimoto⁹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁵First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ⁸Department of Orthopaedic Surgery, Nara Medical University, Nara, Nara, Japan, ⁹Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ¹⁰Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ¹³Kyoto University, Kyoto, Japan, ¹⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: A delay in initiating disease-modifying antirheumatic drugs (DMARDs) has been linked to poor outcomes in patients with rheumatoid arthritis (RA). Several studies have implicated…
Abstract Number: 0535 • ACR Convergence 2024
Oral Glucocorticoid Premedication Is at Least as Effective as Intravenous Glucocorticoid Premedication for Prevention of Infusion-related Reactions to Rituximab in Rheumatoid Arthritis Patients
Pauline Bovens¹, Luuk Van Esveld², Maike Wientjes¹, Noortje van Herwaarden³, David Ten Cate⁴, Eward Melis³, Nienke Lesuis⁵, Bart van den Bemt⁶ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Utrecht, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Rotterdam, Netherlands, ⁵Hospital Group Twente, Almelo, Netherlands, ⁶Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: It has been demonstrated that pretreatment with intravenous glucocorticoids can prevent infusion-related reactions (IRR) that may occur in RA patients receiving rituximab infusions [1].…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0298 • ACR Convergence 2024
RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Miwa Haranaka¹, Akinori Yamada², Saki Takahashi², Keisuke Gotanda², Sonoko Nakano-Kanatani², Nana Uemura², Kensuke Ohnishi², Masanobu Nishidate², Ichio Ohnami² and Megumi Kai³, ¹Souseikai Hakata Clinic, Fukuoka, Japan, ²Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ³Oita University, Oita, Japan
Background/Purpose: Complement C1s is one of the major components of the classical complement pathway (CP), and the abnormal activation of CP is implicated in several…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0435 • ACR Convergence 2024
Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre
Clizia Gagliardi¹, Maria Chiara Gerardi², Eleonora Giacobbe³, Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Bergamo, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: Contraception is a relevant issue for women of childbearing age with immune-mediated rheumatic diseases, as an unplanned pregnancy during active disease or treatment with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].